Lead Product(s) : AMP01
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Amplitude Ventures
Deal Size : $12.0 million
Deal Type : Financing
Reverb Therapeutics Raises $12M To Advance Amplify•R™ Platform
Details : The financing will support Reverb to advance it's lead AMP01 program blocks PD-1 while delivering endogenous IL-15, a key protein that expands and activates cytotoxic T cells.
Product Name : AMP01
Product Type : Antibody
Upfront Cash : Undisclosed
February 19, 2025
Lead Product(s) : AMP01
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Amplitude Ventures
Deal Size : $12.0 million
Deal Type : Financing
Lead Product(s) : Cepharanthine DiHCl
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaTher’s Sairiyo Receives Approval to Start Phase 1 Trial of PD-001 (Cepharanthine)
Details : PD-001 (cepharanthine) is an approved, oral, small molecule natural product candidate. It is being evaluated for the treatment of cancer and covid-19 infection.
Product Name : PD-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 19, 2024
Lead Product(s) : Cepharanthine DiHCl
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ZW191
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zymeworks Announces FDA Clearance of IND for ZW191, Novel Folate Receptor-⍺ ADC
Details : ZW191 is a novel folate receptor-targeted topoisomerase I inhibitor antibody-drug conjugate. Currently, it is being evaluated in the treatment of tumors such as ovarian, endometrial, and lung cancers.
Product Name : ZW191
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 22, 2024
Lead Product(s) : ZW191
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ZW171
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zymeworks: FDA Clears IND for ZW171 Bispecific Antibody for Cancers
Details : ZW171 is a novel 2+1 T-cell targeting bispecific antibody for patients with MSLN-expressing cancers, including ovarian cancer, non-small cell lung cancer, mesothelioma, and other cancers.
Product Name : ZW171
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 17, 2024
Lead Product(s) : ZW171
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bria-Pros+
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BriaCell Announces Prostate Cancer Candidate Bria-Pros+ and Initiates GMP Manufacturing
Details : Bria-Pros+ is a novel off-the-shelf personalized immunotherapy. It is being evaluated in preclinical studies for the treatment of patients with prostate cancer.
Product Name : Bria-Pros+
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 02, 2024
Lead Product(s) : Bria-Pros+
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 225-Ac FPI-2068
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : [225Ac]-FPI-2068 (FPI-2068) is a targeted alpha therapy (TAT) designed to deliver actinium-225 to various solid tumors that express EGFR and cMET. EGFR and cMET are validated cancer targets that are co-expressed in multiple tumor types.
Product Name : FPI-2068
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
December 04, 2023
Lead Product(s) : 225-Ac FPI-2068
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RP-1664
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies. Company expects to initiate clinical trials of RP-1664 in 1H 2024 and RP-3467 in 2H 2024.
Product Name : RP-1664
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2023
Lead Product(s) : RP-1664
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AccuTOX,Nivolumab,Relatlimab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Defence’s Succesfull Accutoxtm Pre-Clinical Efficacy Study Complete Ready for Phase I IND Filing
Details : AccuTOX with anti-PD-1 and anti-LAG3 has shown to be very efficient at impeding tumor growth in many animal models including T-cell lymphoma, breast cancer and melanoma.
Product Name : AccuTOX
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2023
Lead Product(s) : AccuTOX,Nivolumab,Relatlimab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RP-2119
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Ono Pharmaceutical
Deal Size : $175.0 million
Deal Type : Partnership
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals
Details : Under the terms of the Ono Agreement, Repare is primarily responsible for carrying out research activities for its Polθ program, now known as RP-2119, until the first submission of an IND in the U.S. or Japan.
Product Name : RP-2119
Product Type : Other Small Molecule
Upfront Cash : $15.0 million
January 19, 2023
Lead Product(s) : RP-2119
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Ono Pharmaceutical
Deal Size : $175.0 million
Deal Type : Partnership
Lead Product(s) : 225-Ac Vofatamab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FPI-1966 is a targeted alpha therapy designed to target and deliver an alpha emitting medical isotope, actinium-225, to cancer cells expressing FGFR3; a receptor that is overexpressed on several tumor types, including bladder, ovarian and head and neck c...
Product Name : FPI-1966
Product Type : Antibody
Upfront Cash : Inapplicable
August 29, 2022
Lead Product(s) : 225-Ac Vofatamab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable